Daniel Hétu, M.D., MBA

Managing Director

Current investments

Cardiac Dimensions
Gladius Pharmaceuticals
Kalgene Pharmaceuticals
Kisoji Biotech

Previous board roles

Biochem Immunosystems
Resonant Medical (acquired by Elekta)
Veritas Medicine
Zymeworks (Observer)


MD, Université de Sherbrooke, Sherbrooke, Québec
MBA, HEC Montréal, Montréal, Québec

Industry affiliations

Chairman - Scientific Advisory Board of CQDM (pre-competitive research consortium)
Director - HMR (Hôpital Maisonneuve-Rosemont) Foundation
Former Chairman – The center of Excellence for Cellular Therapy at Hôpital Maisonneuve-Rosemont (HMR)
Former Director - Réseau Capital (Québec Venture Capital and Private Equity Association)
Member - Canadian Association of Alternative Strategies & Assets (CAASA)

With over 20 years of investment banking, corporate development, and licensing and investment experience, Daniel has been involved with life sciences companies at all stages of development in North America and overseas. With demonstrated success managing complex initiatives, projects and transactions, Daniel is recognized for his strategic thinking and problem-solving skills.

Daniel’s investment activities are focused on building companies in the therapeutics and medical device sectors that develop products and technologies with a direct and significant impact on patient care. He manages Lumira Ventures’ Montreal office.

An experienced senior executive with leading expertise in financing and corporate business development, Daniel located in Montréal spent 10 years at Shire Pharmaceuticals and at Biochem Pharma prior to its acquisition by Shire. As vice president, business development (North America) and vice president, corporate development, respectively, he led several financing, licensing and M&A transactions in the therapeutics, vaccine and diagnostics sectors. At Biochem, as well as serving on the company’s portfolio committee and the steering committee of strategic research collaborations, Daniel served on the boards of investee companies. Prior to joining Biochem Pharma, Daniel was an investment banker at a major Canadian Investment Bank where he was involved in M&A and financing transactions across various industrial sectors.